Health - Heart latest news

Dyax Corp. (NASDAQ:DYAX) announced positive topline results from its second Phase 3, placebo-controlled trial, EDEMA4, for its lead product candidate DX-88 (ecallantide) for hereditary angioedema (HAE). The EDEMA4 trial, conducted under a Special Protocol Assessment granted by the U.S. Food and Drug Administration (FDA), achieved statistically significant improvements in the intent-to-treat population in primary and secondary endpoints.

Cells obtained from menstrual blood, termed 'endometrial regenerative cells' (ERCs) are capable of restoring blood flow in an animal model of advanced peripheral artery disease. A study published in BioMed Central's open access Journal of Translational medicine demonstrates that when circulation-blocked mice were treated with ERC injections, circulation and functionality were restored.

The credit crunch may be taking its toll, but even if you're feeling the pinch, don't get out of heart healthy habits - a vegetable-rich diet doesn't have to be expensive. There are many ways for you and your family to get your five-a-day without going over-budget - here are some thrifty tips to get started: -Buy loose, whole veg instead of ready-chopped, pre-packed versions that look attractive but are more expensive.

HealthDay - TUESDAY, Aug. 19 (HealthDay News) -- Inexpensive ultrasound imaging may be a simple way to help determine who's at high risk for a heart attack or other cardiovascular issues, a new study says.

Title: Reaching the Heart Through the WristCategory: health newscreated: 8/19/2008 2:00:00 amlast Editorial review: 8/19/2008

Reuters - Reducing levels of the amino acid homocysteine with folic acid and B vitamins failed to prevent serious complications in patients with heart disease, Norwegian researchers said on Tuesday.

HealthDay - TUESDAY, Aug. 19 (HealthDay News) -- A study to determine whether folic acid and vitamin B supplements help the heart has been cut short, because the pills weren't doing any good and might have even caused participants harm.

Pegasus/Heartview LLC (PINKSHEETS: PGUZ) announced that they have now completed the required clinical studies, which are an integral part of the process required for the marketing of the Company's breakthrough HeartVue 6S Heart Screening System in North America.